| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.23 | 1e-08 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.29 | 6e-07 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | -0.18 | 2e-06 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.19 | 3e-06 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | -0.17 | 1e-05 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | 0.16 | 2e-05 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.18 | 2e-05 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.18 | 2e-05 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.24 | 3e-05 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.27 | 6e-05 |